Justin P. Kline to Treatment Outcome
This is a "connection" page, showing publications Justin P. Kline has written about Treatment Outcome.
Connection Strength
0.149
-
Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 2010 Jul; 51(7):1241-50.
Score: 0.037
-
Nelarabine in the treatment of refractory T-cell malignant diseases. Expert Opin Pharmacother. 2006 Sep; 7(13):1791-9.
Score: 0.029
-
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836.
Score: 0.017
-
Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2019 03; 60(3):629-638.
Score: 0.016
-
Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2018 02; 24(2):359-365.
Score: 0.016
-
A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas. Br J Haematol. 2013 Oct; 163(1):55-61.
Score: 0.012
-
A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphoma. J Immunother. 2013 Jul-Aug; 36(6):331-41.
Score: 0.012
-
Influence of related donor age on outcomes after peripheral blood stem cell transplantation. Cytotherapy. 2012 Jul; 14(6):707-15.
Score: 0.011